KPC Pharmaceuticals, Inc. News

KPC Group (600422) focuses on chronic disease management and opens a new chapter in silver hair health strategy

Jul 15 00:00

Kunming Pharmaceutical Group (600422) First Coverage Report: China Resources Empowers to Build a Leader in the Yinfa Economy

Jun 29 00:00

Kunming Pharmaceutical Group (600422): China Resources empowers to build the first stock in the Yinfa economy

Jun 28 00:00

Kunming Pharmaceutical Group (600422): Acquisition of 51% of China Resources Shenghuo's shares to help build a benchmark enterprise in the 37 industrial chain

Jun 13 00:00

Kunming Pharmaceutical Group (600422): Acquiring China Resources Torch to resolve peer competition and build a leader in the Yinfa health industry

Jun 11 07:21

Kunming Pharmaceutical Group (600422): The company plans to acquire 51% of Kunming Shenghuo's shares in cash and continues to be optimistic about the first shares of Yinfa Economic

Jun 10 00:00

Kunming Pharmaceutical Group (600422): The acquisition of China Resources Torch promotes the integration of resources and the accelerated release of 37 industrial products can be expected

Jun 9 00:00

Kunming Pharmaceutical Group (600422): Immediate integration with China Resources Torch to help develop chronic disease management business

Jun 8 00:00

Huayuan Securities released a research report on April 25 stating that it gave Kunming Pharmaceutical Group (600422.SH) a purchase rating. The main reasons for the rating include: 1) deepening the 37 industrial chain and strategically positioning the Yinf

Zhitong FinanceApr 25 16:37

Wanlian Securities released a research report on April 24 stating that it gave China Resources 39 (000999.SZ) a purchase rating. The main reasons for the rating include: 1) the CHC business has achieved rapid growth, and the prescription drug business has

Zhitong FinanceApr 24 20:22

Kunming Pharmaceutical Group (600422): Local fine-tuning is expected to be lower and higher throughout the year

Apr 22 00:00

Kunming Pharmaceutical Group (600422): Steady improvement in business quality, non-growth in line with expectations

Apr 22 00:00

Dongwu Securities released a research report on April 21 stating that it gave KPC Group (600422.SH) a purchase rating. The main reasons for the rating include: 1) the “Kunming Traditional Chinese Medicine 1381” brand has seen initial results, and the thre

Zhitong FinanceApr 21 12:13

Kunming Pharmaceutical Group (600422): The “Kunming Traditional Chinese Medicine 1381” brand achieved initial results, and the three major gold products performed brilliantly

Apr 21 00:00

Kunming Pharmaceutical Group (600422) Company Review Report: Short-term pressure on Q1 performance, Kunming Traditional Chinese Medicine accelerates growth

Apr 20 00:00

Kunming Pharmaceutical Group (600422): Yinfa Health Industry Leader Sets Sail Again in Strategic Reshaping

Apr 18 10:16

Kunming Pharmaceutical Group (600422): Doubling the industrial revenue target by the end of 2028 lays the foundation for medium- to long-term high growth

Mar 29 07:16

Kunming Pharmaceutical Group (600422): Smooth integration strategy clearly released five-year plan to guide growth

Mar 26 12:01

Kunming Pharmaceutical Group (600422): Reform and reshaping, the profit side growth rate is impressive

Mar 26 07:16

Kunming Pharmaceutical Group (600422): Yinfa Industry Strategy Leads Deep Cultivation of Premium Sinopharm and the Sanqi Industrial Chain

Mar 25 00:00